Zacks Investment Research upgraded shares of Aileron Therapeutics (NASDAQ:ALRN) from a sell rating to a hold rating in a research note published on Wednesday, January 10th.
According to Zacks, “Aileron Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It engages in developing and commercializing a novel class of therapeutics primarily in the United States. The companys lead product includes ALRN-6924, targets the tumor suppressor protein p53 for the treatment of a range of cancers which are in clinical stage. Aileron Therapeutics, Inc. is based in Cambridge, Massachusetts. “
Shares of Aileron Therapeutics (NASDAQ ALRN) traded down $0.41 during trading on Wednesday, hitting $9.21. 36,697 shares of the stock were exchanged, compared to its average volume of 35,103. Aileron Therapeutics has a 12 month low of $8.77 and a 12 month high of $15.48.
Aileron Therapeutics (NASDAQ:ALRN) last announced its quarterly earnings results on Thursday, November 9th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.36) by ($0.07). research analysts forecast that Aileron Therapeutics will post -1.76 earnings per share for the current year.
In related news, major shareholder Apple Tree Partners Ii Lp sold 150,000 shares of the stock in a transaction on Tuesday, January 9th. The shares were sold at an average price of $9.80, for a total transaction of $1,470,000.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. 68.10% of the stock is owned by corporate insiders.
Several institutional investors have recently added to or reduced their stakes in ALRN. Neuberger Berman Group LLC purchased a new stake in shares of Aileron Therapeutics in the second quarter valued at about $279,000. Laurion Capital Management LP purchased a new stake in Aileron Therapeutics during the second quarter worth about $335,000. Vanguard Group Inc. purchased a new stake in Aileron Therapeutics during the second quarter worth about $111,000. Citadel Advisors LLC purchased a new stake in Aileron Therapeutics during the second quarter worth about $141,000. Finally, Tudor Investment Corp ET AL purchased a new stake in Aileron Therapeutics during the second quarter worth about $112,000. 7.64% of the stock is currently owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION NOTICE: “Aileron Therapeutics (ALRN) Raised to Hold at Zacks Investment Research” was first published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this news story on another domain, it was illegally stolen and reposted in violation of international trademark and copyright legislation. The original version of this news story can be read at https://ledgergazette.com/2018/01/22/aileron-therapeutics-alrn-stock-rating-upgraded-by-zacks-investment-research.html.
Aileron Therapeutics Company Profile
Aileron Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing a class of therapeutics called stapled peptides. It is also developing a pipeline of stapled peptide drugs across a range of therapeutic areas, including cancer, endocrine and metabolic diseases and inflammation.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aileron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aileron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.